Our research

The research in the Chair of “Prevention of Microbial Disease” focuses on using integrative approaches combining single-cell technologies, culture-independent techniques, multi-omics, and machine learning to understand the underlying mechanisms of phage-host interactions and their impact on the human host.

We apply the knowledge gained to develop novel phage-based therapeutics for i) targeting drug-resistant bacteria, and ii) preventing or iii) ameliorating severity in dysbiosis associated diseases and conditions, such as inflammatory bowel disease (IBD), colorectal cancer (CRC), graft versus host disease (GVHD), allergy, and much more by manipulating the human microbiota.